Exelixis (EXEL) Tops Q1 EPS by 13c, Offers Guidance
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Revenue Growth %: +11.3%
Financial Fact:
Total operating expenses: 61.39M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q1 EPS of $0.26, $0.13 better than the analyst estimate of $0.13. Revenue for the quarter came in at $356 million versus the consensus estimate of $374.75 million.
GUIDANCE:
Exelixis sees FY2022 revenue of $1.53-1.63 billion, versus the consensus of $1.64 billion.
Exelixis is maintaining the following previously provided financial guidance for fiscal year 2022:
Total revenues |
| $1.525 billion - $1.625 billion |
Net product revenues |
| $1.325 billion - $1.425 billion |
Cost of goods sold |
| 5% - 6% of net product revenues |
Research and development expenses (1) |
| $725 million - $775 million |
Selling, general and administrative expenses (2) |
| $400 million - $450 million |
Effective tax rate |
| 20% - 22% |
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion
- Wall Street scrambles to lift Micron price targets ahead of earnings
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
